Citizens Raises Pharvaris Target to $79 on HAE Pipeline

Citizens raised its price target on Pharvaris B.V. (NASDAQ: PHVS) shares to $79 from $75 while maintaining a Market Outperform rating, according to an Investing.com report. The revision, issued by analyst Jonathan Wolleben, highlights clinical momentum in the company's hereditary angioedema treatment portfolio.

Pharvaris stock trades at $37.84, reflecting an upward trajectory over the past year. Shares have climbed 58% over the past 12 months and risen 43% in the last six months, supported by key regulatory milestones and positive trial readouts.

"Citizens raised its price target on Pharvaris B.V. shares to $79 from $75 while maintaining a Market Outperform rating," according to the Investing.com report.

Clinical Trial Data and HAE Treatment Mechanism

The analyst adjustment follows positive topline data from the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant XR. According to the report, the trial demonstrated an 83% reduction in attack rates compared to placebo across the evaluated types of hereditary angioedema. For individuals diagnosed specifically with Type 1 or Type 2 HAE, the reduction reached 87%.

Hereditary angioedema is a rare genetic disorder characterized by unpredictable and painful swelling in various body parts, including the hands, feet, face, and airway. Deucrictibant is an oral bradykinin B2 receptor antagonist designed to inhibit the pathway responsible for these acute swelling attacks, offering patients an oral alternative to traditional injectable therapies.

Wall Street Sentiment and Regulatory Milestones

Pharvaris has attracted positive evaluations from other major financial institutions as its regulatory pipeline advances. Recent analyst actions underscore consensus around the company's commercial prospects:

• Oppenheimer raised its price target to $75 while maintaining an Outperform rating.
• H.C. Wainwright reiterated a Buy rating with a $60 target following the U.S. Food and Drug Administration's acceptance of a New Drug Application for deucrictibant IR capsules.
• Wells Fargo initiated coverage on the stock with an Overweight rating and a $55 price target.

These ratings reflect market interest as pharmaceutical developers work to introduce oral prophylactic and on-demand treatments for rare immunological conditions. With regulatory reviews advancing and late-stage clinical data validating its lead candidate, Pharvaris remains positioned to capture market share in rare disease therapeutics.